Veltuzumab

立即咨询

Veltuzumab

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

728917-18-8

包装与价格：

包装	价格(元)
1mg	电议
5mg	电议

产品名称

IMMU-106
hA20

产品介绍

Veltuzumab (IMMU-106) 是一种人源化抗 CD20 单克隆抗体。Veltuzumab 在 Daudi 细胞系中的EC₅₀值较低，为 0.08-0.09 μg/mL。Veltuzumab 可用于癌症的研究，如非霍奇金淋巴瘤 (NHL)。

生物活性

Veltuzumab (IMMU-106) is ahumanized anti-CD20 monoclonal antibody. Veltuzumab has lowEC₅₀value of 0.08-0.09 μg/mL in the Daudi cell line. Veltuzumab can be used for the research ofcancerincluding non-Hodgkin lymphoma (NHL)^[1].

IC₅₀& Target

EC50: 0.08-0.09 μg/mL (in the Daudi cell line)^[1]

体外研究
(In Vitro)

Veltuzumab significantly reduces off-rates in human lymphoma cell lines, as well as increases complement-dependent cytotoxicity in 1 of 3 cell lines, but no other in vitro differences^[1].
Veltuzumab (0.001-10 μg/mL, 3 h) has low EC₅₀value of 0.08-0.09 μg/mL in the Daudi cell line^[1].

Cell Cytotoxicity Assay^[1]

Cell Line:	4 lymphoma cell lines (SU-DHL-6, Daudi, Raji and WSU-FSCCL)
Concentration:	5 μg/mL
Incubation Time:	4 days
Result:	Had the sensitivity correlated with CD20 expression (SU-DHL6>Raji >Daudi >WSU-FSCCL).

体内研究
(In Vivo)

Veltuzumab (i.v. or s.c.; 5, 20 and 60 μg; single) can control tumor growth or deplete circulating or sessile B cells at low doses in mouse models of intraperitoneal and subcutaneous doses^[1].
Veltuzumab (i.p.; 0.05-35 μg) are significantly effective in vivo^[1].

Animal Model:	Lymphoma xenograft model^[1]
Dosage:	5, 20 and 60 μg
Administration:	intraperitoneal and subcutaneous, single
Result:	Showed low dose of 0.05 μg increased the MST.

Animal Model:	SCID mice^[1]
Dosage:	0.5, 0.25, 0.1, or 0.05 μg; 35, 3.5, 0.35, or 0.035 μg
Administration:	intraperitoneal, single
Result:	Improved significantly survival.

Clinical Trial

CAS 号

728917-18-8

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.